Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy
VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Latest article
Hapbee’s (HAPB) Revolutionary Sleep Aid Lands on the Shelves of Target.
When we first came across Hapbee (HAPB) we described it as having a medical technology (a device) that had the "highest potential...
Adding Cybin (CYBN) to 2024 Top Psychedelic Stocks Watch List.
Steve Cohen from Point 72, Acquires 18,950,000 Shares of Cybin.
ENDRA Life Science’s (NDRA) $1.23 Fatty Liver Detector Advances to Next Stage of Review...
Gentleman start your engines!
Endra (NDRA) recently announced it has advanced to 'substantive review*' with the U.S. Food...
